Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Solid Biosciences is expecting to provide initial safety data on SGT-003 from the first couple of pediatric patients with Duchenne muscular dystrophy enrolled in the phase 1/2 INSPIRE Duchenne trial in mid-2024.

FDA Grants Rare Pediatric Disease Designation to DMD Gene Therapy Candidate SGT-003

Videos

The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]

Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

Building the Archetype for MOGAD Care: Introducing Mayo’s New Clinic

In honor of Huntington Disease Awareness Day, held May 15, 2024, get caught up on some of the latest news in HD, with data updates and expert insights all in one place from the NeurologyLive® team.

Neuro News Roundup: Huntington Disease Awareness Day – Latest Literature

, has been with the team since October 2019. Follow him on Twitter 

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

CMSC 2024: What to Expect From This Year's Annual Meeting

Cure SMA introduces tools aiding in SMA clinical trial navigation and participation empowerment.

Cure SMA Unveils Initiatives to Improve Clinical Trial Accessibility

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

European Committee for Treatment and Research in Multiple Sclerosis Congress

We present a selection of interesting neurology articles for the month of September in the following slides. See the slide legends for links to the article summaries.

Slideshows

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress annually brings together clinicians and researchers in multiple sclerosis (MS) to share the latest data and literature, and interact on the hottest topics in clinical care and therapeutics. Every third year, it meets collectively with its North American counterpart, ACTRIMS.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

Interesting Neuro: ECTRIMS News & Alzheimer Marker